Neural Therapeutics Inc.
NURL
CNSX
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 267.40K | 259.40K | 270.00K | 333.70K | 437.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 383.00K | 428.60K | 481.40K | 567.80K | 708.30K |
| Operating Income | -383.00K | -428.60K | -481.40K | -567.80K | -708.30K |
| Income Before Tax | -398.30K | -447.50K | -490.00K | -474.80K | -600.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.40 | -0.45 | -0.49 | -0.47 | -0.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -398.30K | -447.50K | -490.00K | -474.80K | -600.90K |
| EBIT | -383.00K | -428.60K | -481.40K | -567.80K | -708.30K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 264.06M | 251.60M | 239.90M | 214.61M | 188.20M |
| Average Diluted Shares Outstanding | 264.06M | 251.60M | 239.90M | 214.61M | 188.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |